Ignite Creation Date:
2024-05-06 @ 3:58 AM
Last Modification Date:
2024-10-26 @ 11:42 AM
Study NCT ID:
NCT02428660
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2015-04-21
Brief Title:
Drug Gene Interaction Risk Analysis With Without Genetic Testing Among Patients Undergoing MTM
Sponsor:
Genelex Corporation
Organization:
Genelex Corporation
Study Overview
Official Title:
Medication Therapy Management Combined With Drug and Gene Interaction Software and Cytochrome DNA Testing Among a Population of Polypharmacy Medicare Patients
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This randomized controlled trial will evaluate whether the use of pharmacogenetic testing through a Medication Therapy Management MTM program has a beneficial impact on drug therapy problems More specifically cytochrome DNA testing which provides information with regards to participant specific metabolism of medications will be used in the evaluation of participant medication regimens The overall aim of the project is to evaluate if the addition of genetic CYP testing to a standardized MTM Program provides increased clinical value To answer this question the investigators will look at the drug therapy problems DTPs identified by the genetic test compared to those DTPs discovered without the test
Detailed Description:
All study participants will receive a Comprehensive Medication Review CMR One third will have standard MTM conducted Another third of the participants will be randomized to MTM plus drug interaction risk analysis via YouScript software The remaining third will be randomized to MTM along with drug interaction risk analysis via YouScript software and genetic testing The software will identify polypharmacy patients who may benefit from pharmacogenetic testing based on their current medication regimen Results of the testing will be mailed to both the participant and their provider Participants who undergo testing will also receive a follow-up phone call All participants including those who receive MTM alone will receive a contact 3 months later to assess quality of life
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None